DE69033810T2 - Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper - Google Patents

Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper

Info

Publication number
DE69033810T2
DE69033810T2 DE69033810T DE69033810T DE69033810T2 DE 69033810 T2 DE69033810 T2 DE 69033810T2 DE 69033810 T DE69033810 T DE 69033810T DE 69033810 T DE69033810 T DE 69033810T DE 69033810 T2 DE69033810 T2 DE 69033810T2
Authority
DE
Germany
Prior art keywords
human
protein
production
antibodies against
antibodies
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69033810T
Other languages
English (en)
Other versions
DE69033810D1 (de
Inventor
R King
S Steeg
A Liotta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
National Institutes of Health NIH
Original Assignee
US Department of Health and Human Services
National Institutes of Health NIH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services, National Institutes of Health NIH filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE69033810D1 publication Critical patent/DE69033810D1/de
Publication of DE69033810T2 publication Critical patent/DE69033810T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69033810T 1989-10-18 1990-10-17 Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper Expired - Lifetime DE69033810T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42280189A 1989-10-18 1989-10-18
PCT/US1990/005849 WO1991005793A1 (en) 1989-10-18 1990-10-17 Production and use of human nm23 protein and antibodies therefor

Publications (2)

Publication Number Publication Date
DE69033810D1 DE69033810D1 (de) 2001-10-31
DE69033810T2 true DE69033810T2 (de) 2002-03-28

Family

ID=23676440

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69033810T Expired - Lifetime DE69033810T2 (de) 1989-10-18 1990-10-17 Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper

Country Status (10)

Country Link
US (3) US6423836B1 (de)
EP (1) EP0495910B1 (de)
JP (2) JP2758500B2 (de)
AT (1) ATE206129T1 (de)
AU (1) AU643971B2 (de)
CA (1) CA2067797C (de)
DE (1) DE69033810T2 (de)
DK (1) DK0495910T3 (de)
ES (1) ES2164634T3 (de)
WO (1) WO1991005793A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770386A (en) * 1992-05-20 1998-06-23 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for increasing the sensitivity of a cell to a DNA damaging agent
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6326204B1 (en) 1997-01-17 2001-12-04 Maxygen, Inc. Evolution of whole cells and organisms by recursive sequence recombination
AU6947298A (en) * 1997-04-03 1998-10-22 Joslin Diabetes Center Inc. Modulating the rad-nm23 interaction
WO2002094376A2 (en) * 2001-05-22 2002-11-28 Duke University Compositions and methods for promoting or inhibiting ndpk
GB0124145D0 (en) * 2001-10-08 2001-11-28 Bayer Ag Genes and proteins for prevention,prediction,prognosis and therapy of cardiovascular disease
TWI281473B (en) * 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
US8450279B2 (en) 2007-09-04 2013-05-28 Procell Therapeutics Inc. Cell permeable Nm23 recombinant proteins, polynucleotides encoding the same, and anti-metastatic composition comprising the same
CA2835453A1 (en) * 2011-05-09 2012-11-15 Minerva Biotechnologies Corporation Genetically engineered growth factor variants

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US35097A (en) * 1862-04-29 Improvement in machines for upsetting tires
US4677058A (en) * 1983-05-19 1987-06-30 Karl Tryggvason Detecting malignant cells with monoclonal antibodies specific to type IV collagenase enzyme
US4808528A (en) * 1983-05-19 1989-02-28 Karl Tryggvason Antibody composition for the detection of malignant cells with metastatic cell activity
US4816400A (en) * 1983-05-19 1989-03-28 Karl Tryggvason Basement membrane collagen degrading enzyme and method of purifying same
US5288852A (en) * 1984-03-06 1994-02-22 Dainippon Pharmaceutical Co., Ltd. Human tumor necrosis factor polypeptides
AU5197986A (en) * 1984-11-30 1986-06-18 Whitehead Institute For Biomedical Research Transmissible, mammalian genes associated with tumor metastasis
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
JPH01137994A (ja) * 1987-08-10 1989-05-30 Shionogi & Co Ltd ｒｅｇ蛋白質
US5049662A (en) * 1987-10-13 1991-09-17 The United States Of America As Represented By The Department Of Health And Human Services Kit for diagnosing cancer metastatic potential
JPH01156999A (ja) * 1988-09-03 1989-06-20 Dainippon Pharmaceut Co Ltd ヒト癌壊死因子
FR2653781B1 (fr) * 1989-10-31 1992-02-07 Pasteur Institut Procede de synthese de derives d'adenosine phosphate et derives obtenus.
EP0498849A1 (de) * 1989-10-31 1992-08-19 Institut Pasteur Verfahren zum nachweis vorwiegend proliferierender zellen
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein

Also Published As

Publication number Publication date
ES2164634T3 (es) 2002-03-01
CA2067797C (en) 1997-03-04
JP3295358B2 (ja) 2002-06-24
AU643971B2 (en) 1993-12-02
JPH10212299A (ja) 1998-08-11
ATE206129T1 (de) 2001-10-15
CA2067797A1 (en) 1991-04-19
US6087117A (en) 2000-07-11
JP2758500B2 (ja) 1998-05-28
EP0495910A4 (en) 1993-09-15
JPH04506457A (ja) 1992-11-12
DE69033810D1 (de) 2001-10-31
US6329198B1 (en) 2001-12-11
EP0495910B1 (de) 2001-09-26
EP0495910A1 (de) 1992-07-29
WO1991005793A1 (en) 1991-05-02
AU7042491A (en) 1991-05-16
US6423836B1 (en) 2002-07-23
DK0495910T3 (da) 2002-01-14

Similar Documents

Publication Publication Date Title
MXPA03001645A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
TR200001646T2 (tr) Bir salgılanmış meme kanseri proteini olan mamaglobin.
ATE50500T1 (de) Verwendung von biertreberextrakt zur herstellung von medizinischen und kosmetischen zubereitungen.
DE69111596D1 (de) Verwendung von zwitterionen zur mobilisierung isoelektrisch fokussierter ampholytzonen.
NO974502L (no) Intercellulært domene av HER-2/neu-protein for forhindring eller behandling av malignitet
DE3780618D1 (de) Verwendung von buspiron zur verbesserung des kurzzeitgedaechtnisses.
DE69031656D1 (de) Saccharinderivate zur verwendung als proteolytische enzyminhibitoren sowie verfahren zur herstellung
DK130387D0 (da) Transglutaminase inhibitorer
DE60135315D1 (de) In brust- und blasenkrebs differentiell exprimiertes gen und durch dieses kodierte polypeptide
DE69033810D1 (de) Herstellung und verwendung des menschlichen nm23-h2-proteins und dagegen gerichtete antikörper
DE68921979D1 (de) Antikörper für die antilymphozyten-antikörpertherapie.
IE900141L (en) Acyl-peptide hydrolase and methods of production and use
MXPA03001643A (es) Composiciones y metodos para el diagnostico y tratamiento de tumores.
DE58901722D1 (de) Verwendung von 2-oxo-pyrrolidin-1-acetamid zur bestimmung der glomerulaeren filtrationsrate beim menschen.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE3855080D1 (de) Synoviale phospholipasen
ES8707565A1 (es) Un procedimiento para producir un anticuerpo monoclonal
DE69315341D1 (de) Antigene regionen von tumorfreigestzten partikeln (tlp) komplexen und antikörper die sie erkennen.
DE69128239D1 (de) DNA SEGMENT DES HERPESVIRUS DER MAREK-KRANKHEIT, WELCHES FÜR DAS GLYKOPROTEIN gE KODIERT
DE60135232D1 (de) Nukleinsäure und korrespondierendes protein 85p1b3, nützlich zur behandlung und detektion von krebserkrankungen
DE60042273D1 (de) Antitumorantikörper, proteine und deren verwendung
MXPA03001644A (es) Composiciones y metodos para el diagnostico y tratamiento de tumor.
ATE295874T1 (de) Differenzierungsfaktor der hypophyse und methoden zu seiner verwendung.
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
8364 No opposition during term of opposition